This article, published in the Archives of Dermatological Research, discusses the potential use of selinexor, a selective inhibitor of nuclear export, in the treatment of Merkel cell carcinoma (MCC). MCC is a rare and aggressive form of skin cancer that primarily affects the elderly and immunocompromised. The study found that selinexor significantly downregulated the expression of various genes involved in cellular energy metabolism and cellular proliferation in MCC cells. These findings suggest that selinexor may be a promising treatment option for MCC, but further studies and clinical trials are needed to confirm these results. [Extracted from the article]